These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35178615)

  • 1. Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis.
    Haji S; Sako W; Murakami N; Osaki Y; Izumi Y
    J Neural Transm (Vienna); 2022 Mar; 129(3):301-309. PubMed ID: 35178615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum NFL discriminates Parkinson disease from atypical parkinsonisms.
    Marques TM; van Rumund A; Oeckl P; Kuiperij HB; Esselink RAJ; Bloem BR; Otto M; Verbeek MM
    Neurology; 2019 Mar; 92(13):e1479-e1486. PubMed ID: 30814322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF chitinase proteins in amyotrophic lateral sclerosis.
    Thompson AG; Gray E; Bampton A; Raciborska D; Talbot K; Turner MR
    J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1215-1220. PubMed ID: 31123140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.
    Abu-Rumeileh S; Vacchiano V; Zenesini C; Polischi B; de Pasqua S; Fileccia E; Mammana A; Di Stasi V; Capellari S; Salvi F; Liguori R; Parchi P;
    J Neurol; 2020 Jun; 267(6):1699-1708. PubMed ID: 32100123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
    Halbgebauer S; Steinacker P; Verde F; Weishaupt J; Oeckl P; von Arnim C; Dorst J; Feneberg E; Mayer B; Rosenbohm A; Silani V; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):68-74. PubMed ID: 34417339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of neurofilament light and YKL-40 in cerebrospinal fluid are related to poor outcome in ALS.
    Rosén C; Mitre B; Nellgård B; Axelsson M; Constantinescu R; Andersen PM; Dalla K; Blennow K; Nilsson G; Zetterberg H; Rosén H
    J Neurol Sci; 2024 Aug; 463():123112. PubMed ID: 38972199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis.
    Gille B; De Schaepdryver M; Goossens J; Dedeene L; De Vocht J; Oldoni E; Goris A; Van Den Bosch L; Depreitere B; Claeys KG; Tournoy J; Van Damme P; Poesen K
    Neuropathol Appl Neurobiol; 2019 Apr; 45(3):291-304. PubMed ID: 29908069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis.
    Falzone YM; Domi T; Mandelli A; Pozzi L; Schito P; Russo T; Barbieri A; Fazio R; Volontè MA; Magnani G; Del Carro U; Carrera P; Malaspina A; Agosta F; Quattrini A; Furlan R; Filippi M; Riva N
    Eur J Neurol; 2022 Jul; 29(7):1930-1939. PubMed ID: 35263489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurodegeneration, oxidative stress and lipid metabolism plasma biomarkers to differentiate Parkinson's disease from atypical parkinsonian syndromes.
    Schneider V; Vejux A; Nury T; Dupont G; Pais de Barros JP; Lakomy D; Lizard G; Moreau T
    Rev Neurol (Paris); 2023 Nov; 179(9):961-966. PubMed ID: 37328356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Neurofilament Light With the Development and Severity of Parkinson Disease.
    Halloway S; Desai P; Beck T; Aggarwal N; Agarwal P; Evans D; Rajan KB;
    Neurology; 2022 May; 98(22):e2185-e2193. PubMed ID: 35418452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis.
    Verde F; Steinacker P; Weishaupt JH; Kassubek J; Oeckl P; Halbgebauer S; Tumani H; von Arnim CAF; Dorst J; Feneberg E; Mayer B; Müller HP; Gorges M; Rosenbohm A; Volk AE; Silani V; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):157-164. PubMed ID: 30309882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS.
    Schneider R; Bellenberg B; Gisevius B; Hirschberg S; Sankowski R; Prinz M; Gold R; Lukas C; Haghikia A
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33172960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics.
    Behzadi A; Pujol-Calderón F; Tjust AE; Wuolikainen A; Höglund K; Forsberg K; Portelius E; Blennow K; Zetterberg H; Andersen PM
    Sci Rep; 2021 Nov; 11(1):22128. PubMed ID: 34764380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
    Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
    Front Neurol; 2019; 10():1008. PubMed ID: 31608004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.